Roche's Co-Exclusive License for PI3K Marker Will Aid in Personalization of Genentech Drugs
July 14, 2010
Roche's Co-Exclusive License for PI3K Marker Will Aid in Personalization of Genentech Drugs
Roche announced this week that the co-exclusive license for the biomarker would allow it to develop real-time and endpoint PCR assays to detect mutations in the PI3K oncogene, which would aid its subsidiary Genentech in the development of several investigational drug candidates.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter - Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC
July 27, 2011 / Pharmacogenomics Reporter - Qiagen Says Expanded PCR IP Portfolio Will Boost Hardware and Consumables Sales, Drive Entry into IVD Market
September 24, 2009 / GenomeWeb Daily News - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients
May 15, 2013 / GenomeWeb Daily News